RJA
SNOA icon

Raymond James & Associates’s Sonoma Pharmaceuticals SNOA Stock Holding History

Raymond James & Associates’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-61
Closed -$41K – 3665
2018
Q1 		$41K Buy
+61
New +$50.1K ﹤0.01% 3342
2017
Q2 		– Sell
-62
Closed -$81K – 3427
2017
Q1 		$81K Buy
62
+1
+2% +$1.16K ﹤0.01% 3100
2016
Q4 		$55K Buy
+61
New +$50.6K ﹤0.01% 3091
2016
Q2 		– Sell
-21
Closed -$18K – 3090
2016
Q1 		$18K Buy
+21
New +$19.5K ﹤0.01% 2865

Other funds holding SNOA

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Raymond James & Associates's SNOA Position: Q2 2018 in Review

Raymond James & Associates sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2018, closing a stake of 61 shares — an estimated $41K sold.

Raymond James & Associates first reported a position in SNOA in Q1 2016 and held it in 4 quarters. The position peaked at $81K in Q1 2017. 21 funds tracked by Wall St. Rank hold SNOA as of Q2 2018.

  • Raymond James & Associates reported no remaining Sonoma Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 61 Sonoma Pharmaceuticals shares in Q2 2018, an estimated $41K.
  • Raymond James & Associates first reported a position in Sonoma Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Raymond James & Associates's Sonoma Pharmaceuticals position peaked at $81K in Q1 2017.
  • 21 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.